Virpax Pharmaceuticals, Inc. (VRPX): Price and Financial Metrics
VRPX Price/Volume Stats
| Current price | $3.17 | 52-week high | $11.77 |
| Prev. close | $3.16 | 52-week low | $2.40 |
| Day low | $3.08 | Volume | 4,600 |
| Day high | $3.37 | Avg. volume | 20,535 |
| 50-day MA | $3.73 | Dividend yield | N/A |
| 200-day MA | $5.80 | Market Cap | 3.71M |
VRPX Stock Price Chart Interactive Chart >
Virpax Pharmaceuticals, Inc. (VRPX) Company Bio
Virpax Pharmaceuticals, Inc. is a preclinical stage biopharmaceutical company. The Company focuses on pain management by developing and delivering non-opioid and non-addictive pharmaceutical products using new drug delivery systems and technology.
Latest VRPX News From Around the Web
Below are the latest news stories about VIRPAX PHARMACEUTICALS INC that investors may wish to consider to help them evaluate VRPX as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayIt's time to dive into the biggest pre-market stock movers for Friday morning as we check out the winners and losers today! |
Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q FilingBERWYN, Pa., November 17, 2023--Virpax Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing |
Virpax Pharmaceuticals Announces Leadership TransitionBERWYN, Pa., November 17, 2023--Virpax Announces Leadership Transition |
Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent DevelopmentsBERWYN, Pa., November 15, 2023--Virpax Reports 2023 Third Quarter Results and Recent Developments |
Virpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA ReviewBERWYN, Pa., October 31, 2023--Virpax Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Review |
VRPX Price Returns
| 1-mo | -18.30% |
| 3-mo | 2.23% |
| 6-mo | -55.41% |
| 1-year | -52.50% |
| 3-year | -92.58% |
| 5-year | N/A |
| YTD | -0.97% |
| 2023 | -48.56% |
| 2022 | -81.86% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...